
    
      Patients will be consecutively enrolled in this prospective cross-sectional study, during the
      first 12 months, and then followed for 12 (minimum) up to 24(maximum) months, depending on
      date of patients' enrolment (total study length: 2 years). Patients will be stratified
      according to risk factors and type of treatment carried out in that year
    
  